Kelly Thomas Patrick
Chief Financial Officer
Kelly Thomas Patrick has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Oct 17, 2026.
On the most recent filing, Kelly Thomas Patrick is listed as Chief Financial Officer at Xenon Pharmaceuticals Inc. Inside the rolling window, Kelly Thomas Patrick reported 1 open-market purchase totaling $560K in XENE and no open-market sales.
Companies traded
Other insiders at XENE
Insider Buying
$560K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kelly Thomas Patrick made?
Kelly Thomas Patrick has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Kelly Thomas Patrick trade?
Kelly Thomas Patrick has filed SEC Form 4 disclosures for 1 company, including XENE.
When was Kelly Thomas Patrick's most recent SEC Form 4 filing?
Kelly Thomas Patrick's most recent SEC Form 4 filing on Tracefour is dated Oct 17, 2026.
What is Kelly Thomas Patrick's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Kelly Thomas Patrick is listed as Chief Financial Officer.
What is Kelly Thomas Patrick's total buy and sell value in the current window?
Inside the rolling retention window, Kelly Thomas Patrick bought $560K and sold $0 based on SEC Form 4 filings.
What was Kelly Thomas Patrick's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 15,000 XENE shares on 2026-09-30, worth $560K, per SEC Form 4 filings.